226 related articles for article (PubMed ID: 23307041)
1. High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients.
Chen Y; Xia X; Wang S; Wu X; Zhang J; Zhou Y; Tan Y; He S; Qiang F; Li A; Røe OD; Zhou J
J Gastroenterol; 2013 Sep; 48(9):1034-44. PubMed ID: 23307041
[TBL] [Abstract][Full Text] [Related]
2. MDM2 is a useful prognostic biomarker for resectable gastric cancer.
Ye Y; Li X; Yang J; Miao S; Wang S; Chen Y; Xia X; Wu X; Zhang J; Zhou Y; He S; Tan Y; Qiang F; Li G; Røe OD; Zhou J
Cancer Sci; 2013 May; 104(5):590-8. PubMed ID: 23347235
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer.
Wang S; Wu X; Chen Y; Zhang J; Ding J; Zhou Y; He S; Tan Y; Qiang F; Bai J; Zeng J; Gong Z; Li A; Li G; Røe OD; Zhou J
Clin Cancer Res; 2012 May; 18(10):2987-96. PubMed ID: 22452940
[TBL] [Abstract][Full Text] [Related]
4. VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Thomaidis T; Maderer A; Al-Batran SE; Kany J; Pauligk C; Steinmetz K; Schad A; Hofheinz R; Schmalenberg H; Homann N; Galle PR; Moehler M
BMC Cancer; 2014 Jul; 14():476. PubMed ID: 24981311
[TBL] [Abstract][Full Text] [Related]
5. Synergistic role between p53 and JWA: prognostic and predictive biomarkers in gastric cancer.
Liu X; Wang S; Xia X; Chen Y; Zhou Y; Wu X; Zhang J; He S; Tan Y; Qiang F; Røe OD; Li G; Zhou J
PLoS One; 2012; 7(12):e52348. PubMed ID: 23285001
[TBL] [Abstract][Full Text] [Related]
6. JWA suppresses tumor angiogenesis via Sp1-activated matrix metalloproteinase-2 and its prognostic significance in human gastric cancer.
Chen Y; Huang Y; Huang Y; Xia X; Zhang J; Zhou Y; Tan Y; He S; Qiang F; Li A; Re OD; Li G; Zhou J
Carcinogenesis; 2014 Feb; 35(2):442-51. PubMed ID: 24072772
[TBL] [Abstract][Full Text] [Related]
7. JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients.
Qian J; Zhu W; Wang K; Ma L; Xu J; Xu T; Røe OD; Li A; Zhou J; Shu Y
Oncotarget; 2016 Jun; 7(24):36865-36884. PubMed ID: 27167206
[TBL] [Abstract][Full Text] [Related]
8. Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.
Jeong SH; Han JH; Kim JH; Ahn MS; Hwang YH; Lee HW; Kang SY; Park JS; Choi JH; Lee KJ; Sheen SS; Lim HY
Dig Dis Sci; 2011 Jan; 56(1):131-8. PubMed ID: 20503071
[TBL] [Abstract][Full Text] [Related]
9. Impact of adjuvant chemotherapy cycles on prognosis of resectable stomach cancer: a retrospective analysis.
Zhang WY; Zhang WJ; Bai Y; Yuan HH; Liu F; Gao J; Gong YF; Jiang B
Asian Pac J Cancer Prev; 2013; 14(1):381-6. PubMed ID: 23534757
[TBL] [Abstract][Full Text] [Related]
10. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
11. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Luber B; Deplazes J; Keller G; Walch A; Rauser S; Eichmann M; Langer R; Höfler H; Hegewisch-Becker S; Folprecht G; Wöll E; Decker T; Endlicher E; Lorenzen S; Fend F; Peschel C; Lordick F
BMC Cancer; 2011 Dec; 11():509. PubMed ID: 22152101
[TBL] [Abstract][Full Text] [Related]
12. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.
Qian J; Qian Y; Wang J; Gu B; Pei D; He S; Zhu F; Røe OD; Xu J; Liu L; Gu Y; Guo R; Yin Y; Shu Y; Chen X
Drug Des Devel Ther; 2016; 10():241-58. PubMed ID: 26966350
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy for local advanced gastric cancer].
Shao ZY; Zhang JD
Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(36):2547-9. PubMed ID: 19080647
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
[TBL] [Abstract][Full Text] [Related]
18. RNF185 modulates JWA ubiquitination and promotes gastric cancer metastasis.
Qiu D; Wang Q; Wang Z; Chen J; Yan D; Zhou Y; Li A; Zhang R; Wang S; Zhou J
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1552-1561. PubMed ID: 29481911
[TBL] [Abstract][Full Text] [Related]
19. [Palliative surgery combined with oxaliplatin-based chemotherapy in treatment of patients with advanced gastric cancer].
Chen YB; Guan YX; Zhan YQ; Li W; Sun XW; Li YF; Xu DZ
Ai Zheng; 2004 Nov; 23(11 Suppl):1520-2. PubMed ID: 15566671
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Bang YJ; Kim YW; Yang HK; Chung HC; Park YK; Lee KH; Lee KW; Kim YH; Noh SI; Cho JY; Mok YJ; Kim YH; Ji J; Yeh TS; Button P; Sirzén F; Noh SH;
Lancet; 2012 Jan; 379(9813):315-21. PubMed ID: 22226517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
